PIK3CA mutations in advanced cancers: characteristics and outcomes.

Oncotarget · 2012 · PMC3681495 · PMID 23248156

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp=0.08so close (0.05 < p ≤ 0.1)

Disease-specific subanalyses showed a trend toward an association between PIK3CA and KRAS mutations in colorectal cancer (17/24 [71%] vs. 21/44 [48%]; p=0.08) and associations between PIK3CA mutations and KRAS mutations (6/17 [35%] vs. 2/28 [7%], p=0.04) and MAPK mutations (8/13 [62%] vs. 2/15 [13%], p=0.02) in ovarian and endometrial cancers combined.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.